Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
11Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Beam Therapeutics Inc. (BEAM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
21Total relationships
2Distinct source URLs
5High confidence
0.737Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Beam Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
BIO-PALETTE-CO-LTD
BIO-PALETTE-CO-LTD
90%
the Company has sublicensed from Bio Palette certain patents
KOBE-UNIVERSITY
KOBE-UNIVERSITY
85%
Bio Palette licensed directly from Kobe University
Reciprocal relationship from LLY graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY grap…
Reciprocal relationship from MREO graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from MREO graph: o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9…
Reciprocal relationship from PRME graph: orm is expected to allow Prime Medicine to generate follow-on candidates rapidly and efficiently. In addition, we are identifying partnership opportunities to…
Reciprocal relationship from SANA graph: the University of California (UCSF), our fusogen technology that we acquired from Cobalt Biomedicine, Inc. (Cobalt), and gene editing technology that we licen…
APLS
Apellis Pharmaceuticals, Inc.
62%
Reciprocal relationship from APLS graph: ia, where we received marketing approval in January 2025. We launched SYFOVRE in the United States in March 2023. For the three months ended March 31, 2026 an…
Beam Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
BMY
Bristol-Myers Squibb Company
72%
Reciprocal relationship from BMY graph: Reciprocal relationship from BEAM graph: cess payment obligations are still outstanding as of March 31, 2026 and will continue to be revalued at each reporting…
BMY
Bristol-Myers Squibb Company
72%
cess payment obligations are still outstanding as of March 31, 2026 and will continue to be revalued at each reporting period. Change in fair value of non-controlling equity investments During the th…
BMYMP
Bristol-Myers Squibb Co
72%
cess payment obligations are still outstanding as of March 31, 2026 and will continue to be revalued at each reporting period. Change in fair value of non-controlling equity investments During the th…
BMYMP
Bristol-Myers Squibb Co
72%
Reciprocal relationship from BMYMP graph: Reciprocal relationship from BEAM graph: cess payment obligations are still outstanding as of March 31, 2026 and will continue to be revalued at each reporti…
it of $1.7 billion. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our internal programs and collabor…
Reciprocal relationship from EDIT graph: Reciprocal relationship from BEAM graph: it of $1.7 billion. We expect to continue to incur significant expenses and increasing operating losses in connection…
Reciprocal relationship from SANA graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from SANA graph: the University of California (UCSF), our fusogen technology that we acquired…
BIO-PALETTE-CO-LTD
BIO-PALETTE-CO-LTD
62%
it of $1.7 billion. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our internal programs and collabor…
BROAD-INSTITUTE-EDITAS-MEDICINE-INC
BROAD-INSTITUTE-EDITAS-MEDICINE-INC
62%
it of $1.7 billion. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our internal programs and collabor…
HARVARD-THE-BROAD-INSTITUTE-INC
HARVARD-THE-BROAD-INSTITUTE-INC
62%
it of $1.7 billion. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our internal programs and collabor…
SIXTH-STREET-LENDING-PARTNERS
SIXTH-STREET-LENDING-PARTNERS
62%
ng Rate (SOFR) plus 6.5% (subject to a 1.00% floor). Certain additional commitment, administrative, undrawn amount and facility fees are also payable in connection with the Credit Facility. We are re…
Beam Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BEAM-DEBT-8131
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
BEAM-DEBT
Debt stack $100.3M
90%
Market cache reports total debt of $100.3M.
Beam Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Beam Therapeutics Inc..
Beam Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
BEAM-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 254 tracked holders.
Beam Therapeutics Inc. Extended Supply Chain Network
